Highlights

• Aurobindo Pharma Limited (NSE: AUROPHARMA) fell 4.46% to INR 1,282.30 on 2 April 2026.
• The stock recently faced resistance near the INR 1,340–1,360 zone.
• December 2025 quarter net profit stood at INR 58,207.00 lakh.

Aurobindo Pharma Limited (NSE: AUROPHARMA) came under pressure in Thursday’s session, with the stock slipping 4.46% to INR 1,282.30. The stock opened at INR 1,335.50 and touched an intraday low of INR 1,266.10 after failing to sustain near the day’s high of INR 1,335.50. VWAP for the session stood at INR 1,283.87.

The decline followed a strong upward move seen over the past several weeks. However, the latest chart indicates that Aurobindo Pharma Limited (NSE: AUROPHARMA) has started facing resistance near the INR 1,340.00–1,360.00 area, which may be encouraging a short-term correction after the recent rally.

Fundamental View

For the quarter ended 31 December 2025, Aurobindo Pharma Limited (NSE: AUROPHARMA) reported standalone total income of INR 2,87,743.00 lakh. Profit before tax came in at INR 78,190.00 lakh, while net profit stood at INR 58,207.00 lakh. Earnings per share for the quarter was INR 10.02.

The latest quarterly numbers reflect steady profitability and healthy earnings momentum. Strong operating performance has supported the stock’s recovery over the past few months.

Technical View

Aurobindo Pharma Limited (NSE: AUROPHARMA) is currently trading above its 50-day Simple Moving Average near INR 1,214.49, which suggests that the broader trend remains positive despite the latest decline.

The chart shows that the stock had been forming a rising structure with higher highs and higher lows before encountering selling pressure near the INR 1,340.00 region. After this rejection, the stock slipped sharply toward INR 1,280.00, indicating that the rally may be entering a short consolidation or correction phase.

The 14-day RSI stands near 53.32. Momentum has cooled from recent highs but continues to remain above the neutral 50 mark, suggesting that the longer-term structure has not weakened materially.

If the stock manages to stabilise above the INR 1,250.00–1,280.00 zone, the recent decline may remain a temporary pause within the broader uptrend.

Source: TradingView

Key Technical Levels

Immediate support is seen near INR 1,200.00, while a stronger downside zone is placed around INR 1,100.00. On the upside, resistance remains near INR 1,360.00 and may extend toward INR 1,500.00 if the stock regains momentum.

Risks To Watch

• Failure to hold above INR 1,200.00 may weaken the trend.
• Resistance near INR 1,360.00 may continue to limit upside.
• A deeper correction could emerge if momentum slips below neutral.
• Broader market weakness may increase volatility in the stock.

Summary

Aurobindo Pharma Limited (NSE: AUROPHARMA) declined 4.46% to INR 1,282.30 after encountering resistance near the INR 1,340.00–1,360.00 region. Even after the recent fall, the stock remains above its 50-day moving average near INR 1,214.49, while RSI near 53.32 suggests that the broader trend remains constructive.